Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study to investigate the potential of PBF-999, a novel PDE10 inhibitor, for the treatment of Prader-Willi Syndrome (PWS).

The study is being conducted at the University Hospital Parc Taulí in Sabadell, Spain, under the leadership of Dra. Assumpta Caixàs. The pilot study will evaluate the safety and efficacy of PBF-999 in patients with PWS, a rare genetic disorder that causes a wide range of physical, cognitive, and behavioral problems.

“We are excited to initiate this clinical study to evaluate the potential of PBF-999 for the treatment of Prader-Willi Syndrome,” said Dr. Julio Cesar Castro-Palomino, CEO of Palobiofarma. “PBF-999 has shown promising results in previous clinical studies and we hope that it will be an effective treatment option for patients with this debilitating disorder.”

PBF-999 is a novel PDE10 inhibitor discovered by Palobiofarma, which has demonstrated potent and selective inhibition of the enzyme PDE10 in preclinical studies. PDE10 is an enzyme that regulates the levels of cyclic nucleotides, which are important signalling molecules in the brain. PBF-999 has been evaluated in three previous clinical studies. Observations of an appetite-reducing effect have led Palobiofarma to design a clinical study to test this compound in adults with PWS to evaluate safety and efficacy in the reduction of hyperphagia (excessive hunger)

The study is a randomized, double-blind, cross-over, placebo-controlled trial, with the aim of enrolling approximately 20 patients with PWS. The primary objective will be to evaluate the safety and tolerability of PBF-999 in patients with Prader-Willi Syndrome over 28 days, the study will also explore the effect of PBF-999 in hyperphagia, a hallmark symptom of PWS.

Palobiofarma is committed to improving the lives of patients with serious diseases, and this clinical study represents an important step forward in the development of innovative treatments for Prader-Willi Syndrome.